Where does tirzepatide come from? Lilly's LY3298176

Where does tirzepatide come from?

Tirzepatide is a synthetic peptide designed at Eli Lilly and first published under the research code LY3298176 (Coskun et al., Molecular Metabolism, 2018). Tirzepatide is not extracted from a plant or an animal. Chemists built the molecule on the sequence of GIP, a hormone made in the human gut. The tirzepatide research guide follows the broader evidence record. This article follows a narrower route: an edited hormone sequence became a laboratory code, entered human studies, acquired a generic name, and reached the US medicine label as Mounjaro, with initial US approval in 2022.

The sections below separate the developer, the code name, the molecular construction, the trial path, and the limits of the published record.

Who developed tirzepatide?

Tirzepatide was developed by Eli Lilly through the research program reported by Coskun et al. in Molecular Metabolism in 2018. The paper names the molecule LY3298176 and describes its design and early testing. The same report covers the first-in-human program registered as NCT02759107. In that program, 142 people received the study drug, dulaglutide or placebo between 11 May 2016 and 26 June 2017 at two sites, one in the USA and one in Singapore, in an early-phase study run by the developer (Coskun et al., Molecular Metabolism, 2018). These records tie the molecule's published origin to Lilly rather than to a natural source.

The discovery paper does more than attach a company name. It joins the chemistry, laboratory receptor work, and first human study in one published trail. That trail shows how the candidate moved from molecular design into clinical research while it still carried its internal code.

What is LY3298176?

Tirzepatide and LY3298176 are the same molecule at different naming stages. LY3298176 was Eli Lilly's internal research code in the 2018 discovery paper. Tirzepatide became the generic name used through the later clinical record. Mounjaro became the US brand name when the medicine received initial US approval in 2022, according to the US Mounjaro label (DailyMed, 2 September 2026). The order matters: research code, generic name, then approved brand. Readers looking for a broader comparison can see how the three molecules differ without treating those names as three versions of tirzepatide.

Names can tell readers which part of the record they are holding. A discovery paper may say LY3298176. A scientific article or trial record may say tirzepatide. A US medicine label may say Mounjaro and identify tirzepatide as its active ingredient. The molecule is shared; the regulatory and document context is not.

What is tirzepatide made of?

Tirzepatide is one linear chain of 39 amino acids built on a GIP backbone, with a C20 fatty diacid attached at Lys20 through a linker (Coskun et al., Molecular Metabolism, 2018). Lys20 means the twentieth position is a lysine used as the attachment point. Aib, a non-standard amino acid used instead of a natural one, appears at positions 2 and 13. The fatty diacid is a fatty-acid chain that helps the peptide stick to blood protein. An amidated C-terminus means the tail end is capped. The reported molecular weight is 4810.52 Da (Coskun et al., Molecular Metabolism, 2018).

Willard et al. wrote that tirzepatide was discovered by engineering GLP-1 activity into the GIP sequence (JCI Insight, 2020). In albumin-free laboratory assays, tirzepatide showed binding affinity comparable to natural GIP at the GIP receptor and about five-fold lower binding affinity than natural GLP-1 at the GLP-1 receptor, laboratory findings whose abstract gives no sample count and that do not establish effects in people (Willard et al., JCI Insight, 2020). That imbalance was part of the design, not evidence that the molecule was harvested from either hormone.

The sequence and its attached chain explain more about origin than a formula alone. A nearby article gives retatrutide's molecular formula, but tirzepatide follows its own design record and has the formula C225H348N48O68 (Coskun et al., Molecular Metabolism, 2018).

Is tirzepatide made from a natural source?

Tirzepatide is not identified in the published record as a plant extract or an animal isolate. Tirzepatide is a synthetic peptide built by editing the sequence of human GIP (Coskun et al., Molecular Metabolism, 2018; Willard et al., JCI Insight, 2020). The natural part is the starting idea: the human gut already makes GIP as a signalling hormone. The finished molecule is different. Chemists changed selected amino acids and attached a fatty diacid chain. The result is a designed laboratory molecule based on a human hormone sequence, not that hormone collected from the body.

A useful distinction is the difference between copying a pattern and collecting a substance. A written melody can inspire a new arrangement without being taken from a live performance. In the same way, the GIP sequence provided a molecular pattern. The Lilly program then edited that pattern into LY3298176.

Is tirzepatide a peptide?

Yes. Tirzepatide is a synthetic peptide: a linear chain of 39 amino acids with a C20 fatty diacid attached through a linker (Coskun et al., Molecular Metabolism, 2018). The TGA's assessment report for Mounjaro calls tirzepatide "a synthetic peptide, engineered from the native GIP peptide sequence" (TGA AusPAR, 20 September 2024). The FDA's December 2023 draft guidance on peptide drug products uses the word peptide for any polymer of 40 or fewer amino acids, and tirzepatide's 39 sits just under that line. A peptide is a short chain of amino acids, the building blocks of proteins.

The two words in "synthetic peptide" do two jobs. "Peptide" names the structure, a chain of amino acids. "Synthetic" says chemists built the chain instead of taking it from a living source. The 2018 discovery paper states that the compounds it tested were made at Eli Lilly "using traditional peptide chemistry methods" (Coskun et al., Molecular Metabolism, 2018).

Your own body makes peptides all day long. Insulin is one, and so are GIP and GLP-1. What sets tirzepatide apart is that it is an edited copy rather than a body-made original. The tirzepatide hub follows the molecule through its safety, study, legal and half-life records.

Is tirzepatide a peptide hormone?

Tirzepatide is a peptide medicine built on a peptide hormone's sequence, but it is not itself a natural hormone. GIP, the hormone whose sequence tirzepatide edits, is released from K cells in the upper small intestine in response to food (Coskun et al., Molecular Metabolism, 2018). Tirzepatide is a laboratory-made analogue, meaning an edited copy: it carries two Aib residues, an amidated tail and a fatty diacid. The US label describes tirzepatide as a GIP receptor and GLP-1 receptor agonist, a molecule that switches those two receptors on (US Mounjaro label, DailyMed, 2 September 2026).

The difference between a hormone and a hormone-like drug matters for naming. A hormone is a signal the body makes. An analogue is a molecule made to carry a similar signal. A 2020 laboratory study of cell signalling and primary islets reports that tirzepatide mimics the actions of natural GIP at the GIP receptor, and an occupancy calculation for clinically studied doses found greater engagement of the GIP receptor than the GLP-1 receptor, which the authors, who include developer employees, call an imbalanced mechanism of action, calculated from laboratory data, with no sample count in the abstract, and not measured in people (Willard et al., JCI Insight, 2020).

Is Ozempic a peptide, and is semaglutide a peptide?

Ozempic is a brand name, and the peptide inside it is semaglutide: a GLP-1 analogue with 94% sequence homology to human GLP-1 (US Ozempic label, DailyMed, 10 June 2026). Lau et al. report that semaglutide has two amino acid substitutions compared with human GLP-1 and carries a fatty-acid derivative at lysine 26 (Journal of Medicinal Chemistry, 2015). The answer to "Is semaglutide a peptide?" and "Is Ozempic a peptide?" is therefore yes, with one wording point: the medicine is the product, and the peptide is its active ingredient.

The Ozempic label states that semaglutide's peptide backbone is produced by yeast fermentation and then modified with a fatty di-acid (US Ozempic label, DailyMed, 10 June 2026). Tirzepatide's discovery paper describes material made by chemical peptide synthesis, and the TGA calls tirzepatide a synthetic peptide. Both are peptides. The routes that make the chains differ.

None of these descriptions applies to research material sold for laboratory work. The labels describe approved medicines, made and tested under regulatory review.

How do tirzepatide and semaglutide differ as molecules?

Tirzepatide and semaglutide are both fatty-acid-modified peptides, and they differ in four ways: the hormone sequence each is built on, the receptors each switches on, the fatty chain each carries, and the way the chain is made. Tirzepatide is built on the GIP sequence and acts on the GIP and GLP-1 receptors (US Mounjaro label, DailyMed, 2 September 2026). Semaglutide is built on the GLP-1 sequence and acts on the GLP-1 receptor (US Ozempic label, DailyMed, 10 June 2026). The table below sets the two records side by side.

The label molecular weights differ from the discovery paper's by a few daltons: the 2018 paper reports 4810.52 Da for tirzepatide and the US label reports 4813.53 Da. Neither document explains the gap, so this page does not either.

How did tirzepatide go from a lab code to an approved medicine?

Tirzepatide moved from the 2018 LY3298176 discovery paper into a 26-week Phase 2 trial in type 2 diabetes, then the 40-week Phase 3 monotherapy trial SURPASS-1, before US approval as Mounjaro in 2022. In the Phase 2 trial of 318 randomised adults with type 2 diabetes, HbA1c changes ran from −1.06% to −1.94% across four tirzepatide groups, compared with −0.06% for placebo, a result for that small early-phase trial that does not describe other populations (Frías et al., Lancet, 2018). In SURPASS-1, which randomised 478 adults with type 2 diabetes inadequately controlled by diet and exercise alone across 52 centres, HbA1c changes ran from −1.87% to −2.07% across three tirzepatide groups, compared with +0.04% for placebo, a result for that population only (Rosenstock et al., Lancet, 2021).

The stages answer different questions. Discovery work explains how the molecule was built. Later trials test defined outcomes in defined groups. The US Mounjaro label then records Mounjaro as a GIP and GLP-1 receptor agonist with initial US approval in 2022.

Research-use material sold for laboratory work is not that approved medicine. The listing for tirzepatide reference material gives catalog lot and historical sample-report context; matching current certification is unverified. The wider timeline for how long retatrutide has been studied follows a separate molecule and is not folded into tirzepatide's record.

Evidence limits

What does the research not show?

The US Mounjaro label does not establish Australian TGA status and does not make any research material Mounjaro. Research-use tirzepatide is not a medicine, not a substitute for one, and not for human or animal use. The label describes an approved US product with its own manufacturing and regulatory record; it does not transfer that status to a laboratory reference item.

Eli Lilly sponsored all four papers, and most of the authors were Lilly employees.